Mabwell Reports the US FDA’s IND Approval of 7MW3711 for the Treatment of Solid Tumors
Shots:
- Mabwell has received the IND approval from the US FDA to commence the clinical trial of 7MW3711, developed by ADC platform IDDC, for treating advanced malignant solid tumor. The clinical study of 7MW3711 has begun in China
- The IND approval was based on the preclinical results that demonstrated 7MW3711’s ability to destroy tumor cells in various animal models along with favorable safety profile & PK characteristics in the safety animal models incl. cynomolgus monkeys
- The company’s 7MW3711 comprises of an innovative Ab molecule, novel linker & novel payload (topoisomerase I inhibitor). It targets tumor cell surface antigens for releasing cytotoxic drug to trigger tumor cell apoptosis
Ref: PR Newswire | Image: Mabwell
Related News:- Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
